Nevertheless, anti-ROR2 ADCs and ROR2-specific CAR-T cells are clinically evaluated in solid malignancies and in phase I/II in renal cell carcinoma, respectively [98]. This evidence concerns the gene ROR2 and hereditary clear cell renal cell carcinoma.